Miglustat (Mig) was launched in 2002 as a chemotherapy drug for the treatment of Gaucher's disease and Niemann Pick's disease type C. Mig is an inhibitor of targeting UDP-glucose ceramide glycosyltransferase (UGCG), which decreases the activity of UGCG, reduces the synthesis of glucose ceramides, and thereby inhibiting the synthesis of more complex Glycosphingolipids (GSLs) and preventing the accumulation of glycolytic enzyme volume (McCormack and Goa et al. 2003). The gene discussed is CXCL9; the disease is Niemann-Pick disease type C.